 Mark Gerich
Concepts (233)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Crohn Disease | 9 | 2022 | 211 | 1.870 |
Why?
| | Inflammatory Bowel Diseases | 10 | 2025 | 311 | 1.480 |
Why?
| | Medical Marijuana | 4 | 2017 | 108 | 1.390 |
Why?
| | Immunosuppressive Agents | 5 | 2020 | 699 | 1.290 |
Why?
| | Gastrointestinal Diseases | 3 | 2016 | 197 | 1.260 |
Why?
| | Colitis | 10 | 2024 | 240 | 1.050 |
Why?
| | Thalidomide | 2 | 2015 | 30 | 0.950 |
Why?
| | Colitis, Ulcerative | 6 | 2024 | 114 | 0.940 |
Why?
| | Intestinal Mucosa | 8 | 2024 | 570 | 0.800 |
Why?
| | Drug Resistance | 1 | 2013 | 167 | 0.400 |
Why?
| | Salvage Therapy | 1 | 2013 | 136 | 0.390 |
Why?
| | Tacrolimus | 1 | 2013 | 145 | 0.390 |
Why?
| | Intestines | 3 | 2021 | 347 | 0.390 |
Why?
| | Proctocolectomy, Restorative | 1 | 2011 | 19 | 0.370 |
Why?
| | Colonic Pouches | 1 | 2011 | 14 | 0.370 |
Why?
| | Intestinal Neoplasms | 1 | 2011 | 28 | 0.360 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2022 | 1204 | 0.350 |
Why?
| | Mercaptopurine | 1 | 2010 | 15 | 0.350 |
Why?
| | Antiporters | 2 | 2021 | 22 | 0.350 |
Why?
| | Spondylitis, Ankylosing | 2 | 2021 | 45 | 0.350 |
Why?
| | Allopurinol | 1 | 2010 | 58 | 0.340 |
Why?
| | Precision Medicine | 1 | 2013 | 386 | 0.330 |
Why?
| | Acidosis | 2 | 2021 | 88 | 0.330 |
Why?
| | Enzyme Inhibitors | 2 | 2010 | 829 | 0.320 |
Why?
| | Spondylarthritis | 2 | 2021 | 45 | 0.320 |
Why?
| | Dextran Sulfate | 6 | 2024 | 76 | 0.310 |
Why?
| | Gastrointestinal Microbiome | 3 | 2022 | 635 | 0.310 |
Why?
| | Algorithms | 3 | 2020 | 1626 | 0.310 |
Why?
| | Colon | 2 | 2020 | 246 | 0.300 |
Why?
| | Neutrophils | 3 | 2024 | 1205 | 0.290 |
Why?
| | Tryptophan | 2 | 2021 | 168 | 0.290 |
Why?
| | Ileitis | 2 | 2021 | 32 | 0.280 |
Why?
| | Patient Acceptance of Health Care | 3 | 2022 | 764 | 0.270 |
Why?
| | Antibodies, Monoclonal | 1 | 2013 | 1361 | 0.260 |
Why?
| | Endocannabinoids | 2 | 2017 | 40 | 0.250 |
Why?
| | Disease Models, Animal | 8 | 2024 | 3999 | 0.250 |
Why?
| | MicroRNAs | 2 | 2024 | 669 | 0.230 |
Why?
| | Legislation, Drug | 2 | 2016 | 81 | 0.230 |
Why?
| | Tight Junction Proteins | 1 | 2024 | 14 | 0.230 |
Why?
| | Humans | 37 | 2025 | 129078 | 0.230 |
Why?
| | Adenocarcinoma | 1 | 2011 | 898 | 0.220 |
Why?
| | United States Food and Drug Administration | 2 | 2016 | 204 | 0.220 |
Why?
| | Th1 Cells | 1 | 2024 | 135 | 0.220 |
Why?
| | Peroxidase | 1 | 2024 | 183 | 0.220 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2024 | 86 | 0.210 |
Why?
| | Colonic Polyps | 1 | 2024 | 86 | 0.200 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2024 | 245 | 0.200 |
Why?
| | Inflammation | 5 | 2024 | 2696 | 0.200 |
Why?
| | Microbiota | 2 | 2022 | 724 | 0.200 |
Why?
| | Colonoscopy | 1 | 2024 | 225 | 0.190 |
Why?
| | Infliximab | 3 | 2020 | 102 | 0.190 |
Why?
| | Metabolomics | 3 | 2022 | 594 | 0.190 |
Why?
| | Artificial Intelligence | 1 | 2024 | 233 | 0.180 |
Why?
| | Ustekinumab | 1 | 2020 | 13 | 0.180 |
Why?
| | Plasma Membrane Neurotransmitter Transport Proteins | 1 | 2020 | 4 | 0.170 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2021 | 138 | 0.170 |
Why?
| | Mucin 5AC | 1 | 2020 | 69 | 0.170 |
Why?
| | Killer Cells, Natural | 1 | 2023 | 424 | 0.170 |
Why?
| | Gastrointestinal Agents | 1 | 2020 | 62 | 0.170 |
Why?
| | Male | 17 | 2025 | 63248 | 0.170 |
Why?
| | Metagenomics | 1 | 2021 | 153 | 0.160 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2021 | 200 | 0.160 |
Why?
| | Quality Assurance, Health Care | 1 | 2021 | 320 | 0.160 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1842 | 0.160 |
Why?
| | Membrane Transport Proteins | 1 | 2020 | 148 | 0.160 |
Why?
| | Adult | 13 | 2025 | 35423 | 0.150 |
Why?
| | Receptors, Cannabinoid | 2 | 2017 | 14 | 0.150 |
Why?
| | Intraepithelial Lymphocytes | 1 | 2018 | 14 | 0.150 |
Why?
| | Health Care Costs | 1 | 2021 | 404 | 0.150 |
Why?
| | Receptors, Interleukin-10 | 1 | 2018 | 6 | 0.150 |
Why?
| | Middle Aged | 10 | 2024 | 31024 | 0.150 |
Why?
| | Thrombophilia | 1 | 2018 | 68 | 0.150 |
Why?
| | Microfluidic Analytical Techniques | 1 | 2018 | 72 | 0.140 |
Why?
| | Ambulatory Care | 1 | 2021 | 509 | 0.140 |
Why?
| | Mice, Knockout | 5 | 2024 | 2774 | 0.140 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2023 | 833 | 0.140 |
Why?
| | Interleukin-10 Receptor alpha Subunit | 1 | 2017 | 5 | 0.140 |
Why?
| | Thrombelastography | 1 | 2018 | 148 | 0.140 |
Why?
| | Quality of Health Care | 1 | 2021 | 610 | 0.140 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 51 | 0.130 |
Why?
| | Mice | 11 | 2024 | 16583 | 0.130 |
Why?
| | Fecal Microbiota Transplantation | 1 | 2016 | 18 | 0.130 |
Why?
| | Cannabinoids | 2 | 2017 | 132 | 0.130 |
Why?
| | Nerve Tissue Proteins | 1 | 2020 | 570 | 0.130 |
Why?
| | Female | 13 | 2025 | 68274 | 0.130 |
Why?
| | Myeloid Cells | 1 | 2017 | 140 | 0.130 |
Why?
| | Clostridium Infections | 1 | 2016 | 57 | 0.130 |
Why?
| | Drug and Narcotic Control | 1 | 2016 | 28 | 0.130 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2017 | 154 | 0.130 |
Why?
| | Inflammasomes | 1 | 2017 | 129 | 0.120 |
Why?
| | Hospitalization | 2 | 2022 | 2080 | 0.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 750 | 0.120 |
Why?
| | Indoles | 1 | 2018 | 378 | 0.120 |
Why?
| | Delivery of Health Care | 1 | 2021 | 896 | 0.110 |
Why?
| | Nausea | 1 | 2014 | 105 | 0.110 |
Why?
| | Steroids | 1 | 2014 | 148 | 0.110 |
Why?
| | Mice, Inbred C57BL | 5 | 2024 | 5282 | 0.110 |
Why?
| | Vomiting | 1 | 2014 | 129 | 0.110 |
Why?
| | Case-Control Studies | 5 | 2021 | 3336 | 0.110 |
Why?
| | Retrospective Studies | 5 | 2022 | 14562 | 0.110 |
Why?
| | Anti-Inflammatory Agents | 1 | 2017 | 468 | 0.110 |
Why?
| | Animals | 12 | 2024 | 34708 | 0.100 |
Why?
| | United States | 4 | 2021 | 13992 | 0.100 |
Why?
| | Attitude to Health | 1 | 2016 | 425 | 0.100 |
Why?
| | Prospective Studies | 4 | 2024 | 7070 | 0.100 |
Why?
| | alpha 1-Antitrypsin | 1 | 2013 | 111 | 0.100 |
Why?
| | Tight Junctions | 2 | 2024 | 74 | 0.100 |
Why?
| | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2011 | 14 | 0.090 |
Why?
| | Administration, Oral | 1 | 2013 | 784 | 0.090 |
Why?
| | Guanine Nucleotides | 1 | 2010 | 15 | 0.090 |
Why?
| | Thionucleotides | 1 | 2010 | 34 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 1974 | 0.090 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 339 | 0.080 |
Why?
| | Methyltransferases | 1 | 2010 | 72 | 0.080 |
Why?
| | Chronic Disease | 3 | 2022 | 1717 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2021 | 4927 | 0.080 |
Why?
| | Genotype | 1 | 2013 | 1835 | 0.080 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 760 | 0.070 |
Why?
| | Procollagen-Proline Dioxygenase | 1 | 2008 | 27 | 0.070 |
Why?
| | Prognosis | 2 | 2013 | 3793 | 0.070 |
Why?
| | Hypoxia-Inducible Factor 1 | 1 | 2008 | 75 | 0.070 |
Why?
| | Disease Susceptibility | 2 | 2021 | 338 | 0.070 |
Why?
| | Cost-Benefit Analysis | 2 | 2020 | 616 | 0.070 |
Why?
| | Treatment Outcome | 2 | 2025 | 10256 | 0.060 |
Why?
| | Homeostasis | 2 | 2020 | 605 | 0.060 |
Why?
| | Young Adult | 2 | 2013 | 12310 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 1 | 2013 | 2273 | 0.060 |
Why?
| | Immunity, Innate | 1 | 2011 | 804 | 0.060 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2025 | 61 | 0.060 |
Why?
| | Halogenation | 1 | 2024 | 20 | 0.060 |
Why?
| | Remission Induction | 1 | 2025 | 269 | 0.060 |
Why?
| | T-Box Domain Proteins | 1 | 2024 | 96 | 0.060 |
Why?
| | Canada | 1 | 2025 | 355 | 0.060 |
Why?
| | Multicenter Studies as Topic | 1 | 2025 | 288 | 0.060 |
Why?
| | Prevalence | 1 | 2010 | 2541 | 0.050 |
Why?
| | Cell Line | 2 | 2020 | 2762 | 0.050 |
Why?
| | Immunoglobulins | 1 | 2023 | 158 | 0.050 |
Why?
| | Receptors, KIR | 1 | 2023 | 96 | 0.050 |
Why?
| | Phosphorylation | 2 | 2021 | 1686 | 0.050 |
Why?
| | Adenoma | 1 | 2024 | 210 | 0.050 |
Why?
| | Thymus Gland | 1 | 2023 | 307 | 0.050 |
Why?
| | Phenotype | 1 | 2010 | 3062 | 0.050 |
Why?
| | Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2021 | 12 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 332 | 0.050 |
Why?
| | Dual Specificity Phosphatase 1 | 1 | 2021 | 26 | 0.050 |
Why?
| | Patient Reported Outcome Measures | 1 | 2025 | 360 | 0.050 |
Why?
| | Cost Savings | 1 | 2021 | 83 | 0.050 |
Why?
| | Ligands | 1 | 2023 | 616 | 0.050 |
Why?
| | Granzymes | 1 | 2021 | 47 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2021 | 173 | 0.040 |
Why?
| | Ileum | 1 | 2021 | 113 | 0.040 |
Why?
| | Adalimumab | 1 | 2020 | 45 | 0.040 |
Why?
| | Azathioprine | 1 | 2020 | 48 | 0.040 |
Why?
| | Protective Factors | 1 | 2020 | 91 | 0.040 |
Why?
| | Organoids | 1 | 2021 | 100 | 0.040 |
Why?
| | Leukocyte Disorders | 1 | 2019 | 10 | 0.040 |
Why?
| | Sodium Dodecyl Sulfate | 1 | 2019 | 22 | 0.040 |
Why?
| | Models, Economic | 1 | 2020 | 56 | 0.040 |
Why?
| | Markov Chains | 1 | 2020 | 125 | 0.040 |
Why?
| | Quality-Adjusted Life Years | 1 | 2020 | 116 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2021 | 176 | 0.040 |
Why?
| | Transendothelial and Transepithelial Migration | 1 | 2019 | 30 | 0.040 |
Why?
| | Gene Expression Regulation | 2 | 2021 | 2523 | 0.040 |
Why?
| | Immune System Diseases | 1 | 2019 | 33 | 0.040 |
Why?
| | Colectomy | 1 | 2020 | 94 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2021 | 312 | 0.040 |
Why?
| | Neutrophil Activation | 1 | 2019 | 79 | 0.040 |
Why?
| | Dysbiosis | 1 | 2021 | 166 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2025 | 1367 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2020 | 315 | 0.040 |
Why?
| | Feces | 1 | 2022 | 430 | 0.040 |
Why?
| | Surgical Wound Infection | 1 | 2022 | 291 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 422 | 0.040 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2021 | 321 | 0.040 |
Why?
| | Aged, 80 and over | 1 | 2010 | 7063 | 0.040 |
Why?
| | Aged | 2 | 2024 | 22068 | 0.040 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2024 | 1044 | 0.040 |
Why?
| | Adenosine | 1 | 2019 | 213 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2020 | 521 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 1020 | 0.030 |
Why?
| | Receptors, CCR2 | 1 | 2017 | 39 | 0.030 |
Why?
| | Pilot Projects | 1 | 2022 | 1548 | 0.030 |
Why?
| | Biological Products | 1 | 2020 | 202 | 0.030 |
Why?
| | Clinical Competence | 1 | 2024 | 1021 | 0.030 |
Why?
| | Child | 2 | 2022 | 20860 | 0.030 |
Why?
| | Colorectal Neoplasms | 1 | 2024 | 731 | 0.030 |
Why?
| | Computational Biology | 1 | 2021 | 588 | 0.030 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2017 | 52 | 0.030 |
Why?
| | Up-Regulation | 1 | 2019 | 850 | 0.030 |
Why?
| | Biopsy | 1 | 2020 | 1093 | 0.030 |
Why?
| | Kynurenine | 1 | 2017 | 103 | 0.030 |
Why?
| | Hematopoiesis | 1 | 2017 | 184 | 0.030 |
Why?
| | Adaptation, Physiological | 1 | 2019 | 516 | 0.030 |
Why?
| | Signal Transduction | 2 | 2021 | 4867 | 0.030 |
Why?
| | Child, Preschool | 1 | 2010 | 10462 | 0.030 |
Why?
| | Antibodies | 1 | 2017 | 393 | 0.030 |
Why?
| | Incidence | 1 | 2021 | 2635 | 0.030 |
Why?
| | Interleukin-1beta | 1 | 2017 | 376 | 0.030 |
Why?
| | Interleukin-10 | 1 | 2017 | 299 | 0.030 |
Why?
| | Energy Metabolism | 1 | 2020 | 837 | 0.030 |
Why?
| | Wound Healing | 1 | 2017 | 310 | 0.030 |
Why?
| | Mitochondria | 1 | 2020 | 840 | 0.030 |
Why?
| | Monocytes | 1 | 2017 | 553 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1696 | 0.030 |
Why?
| | Bacteria | 1 | 2020 | 812 | 0.030 |
Why?
| | Epithelial Cells | 1 | 2020 | 1063 | 0.030 |
Why?
| | Interferon-gamma | 1 | 2017 | 759 | 0.030 |
Why?
| | Base Sequence | 1 | 2017 | 2157 | 0.030 |
Why?
| | Cell Membrane Permeability | 1 | 2013 | 82 | 0.030 |
Why?
| | Quality of Life | 1 | 2025 | 2711 | 0.030 |
Why?
| | Nanoparticles | 1 | 2017 | 358 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1913 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2017 | 1195 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2019 | 4063 | 0.020 |
Why?
| | Cohort Studies | 1 | 2022 | 5400 | 0.020 |
Why?
| | Granulocytes | 1 | 2011 | 79 | 0.020 |
Why?
| | Adolescent | 1 | 2010 | 20241 | 0.020 |
Why?
| | Time Factors | 1 | 2021 | 6579 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2011 | 149 | 0.020 |
Why?
| | Acute Disease | 1 | 2013 | 978 | 0.020 |
Why?
| | Pancreatic Neoplasms | 1 | 2018 | 878 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2013 | 1147 | 0.020 |
Why?
| | STAT3 Transcription Factor | 1 | 2011 | 187 | 0.020 |
Why?
| | ROC Curve | 1 | 2011 | 501 | 0.020 |
Why?
| | Down-Regulation | 1 | 2011 | 639 | 0.020 |
Why?
| | HeLa Cells | 1 | 2008 | 602 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 1968 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2008 | 350 | 0.020 |
Why?
| | Cytokines | 1 | 2013 | 1997 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2011 | 2702 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2011 | 2768 | 0.010 |
Why?
| | Colorado | 1 | 2011 | 4445 | 0.010 |
Why?
| | Biomarkers | 1 | 2011 | 3878 | 0.010 |
Why?
|
|
Gerich's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|